Last reviewed · How we verify
NCT04798066
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome
NO LONGER AVAILABLE
Last updated 29 September 2025
What this trial tests
trial testing HB-adMSCs in Post COVID-19 Syndrome. No longer available.
Quick facts
| Lead sponsor | Hope Biosciences Research Foundation |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- HB-adMSCs — full drug profile →
Conditions studied
- Post COVID-19 Syndrome — all drugs for Post COVID-19 Syndrome →
Sponsor
Hope Biosciences Research Foundation
Who can join
Adults 18 to 65, any sex, with Post COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an Intermediate- Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with Post-COVID-19 Syndrome. The investigational product will be an add-on treatment to the standard of care.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases.
Soares MBP, Gonçalves RGJ, Vasques JF, da Silva-Junior AJ, et al · · 2022 · cited 16× · PMID 35782379 · DOI 10.3389/fnmol.2022.883378 -
Emerging Landscape of Mesenchymal Stem Cell Senescence Mechanisms and Implications on Therapeutic Strategies.
Wang J, Zhang M, Wang H. · · 2024 · cited 13× · PMID 39144566 · DOI 10.1021/acsptsci.4c00284 -
Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program.
Vij R, Kim H, Park H, Cheng T, et al · · 2023 · cited 6× · PMID 37798650 · DOI 10.1186/s13287-023-03522-1 -
Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends.
Javed A, Karki S, Sami Z, Khan Z, et al · · 2022 · cited 5× · PMID 35782071 · DOI 10.1155/2022/9346939 -
The effects of long COVID-19, its severity, and the need for immediate attention: Analysis of clinical trials and Twitter data.
Bhattacharyya A, Seth A, Rai S. · · 2022 · cited 4× · PMID 36588926 · DOI 10.3389/fdata.2022.1051386 -
Stem cell therapy for COVID-19 pneumonia.
Kebria MM, Milan PB, Peyravian N, Kiani J, et al · · 2022 · cited 4× · PMID 35174448 · DOI 10.1186/s43556-021-00067-8 -
Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair.
Carbone-Schellman J, Fontecilla-Escobar J, Sales-Salinas N, Chaparro-Pico WF, et al · · 2025 · cited 1× · PMID 41235241 · DOI 10.3389/fimmu.2025.1677433 -
The Effects of Long COVID-19, its Severity, and the Need for Immediate Attention: Analysis of Clinical Trials and Twitter data
Bhattacharyya A, Seth A, Rai S. · · 2022 · DOI 10.1101/2022.09.13.22279833
Verify or expand the search:
- PubMed search for NCT04798066
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HB-adMSCs
Trials testing the same drug.
- NCT05116540 — Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis · Phase 2 · completed
- NCT04928287 — Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate) · Phase 2 · completed
- NCT04348435 — A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19. · Phase 2 · completed
- NCT04349631 — A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19 · Phase 2 · completed
- NCT04228666 — A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-a · Phase 1, PHASE2 · withdrawn
Other recruiting trials for Post COVID-19 Syndrome
Currently open trials in the same condition.
- NCT07110714 — Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients · NA · recruiting
- NCT07051954 — Effectiveness of Functional Respiratory Muscle Training in Post-COVID-19 Syndrome · NA · recruiting
Other Hope Biosciences Research Foundation trials
Trials by the same sponsor.
- NCT05126563 — Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome · Phase 2 · completed
- NCT05116540 — Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis · Phase 2 · completed
- NCT04995081 — Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) · Phase 2 · completed
- NCT04928287 — Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate) · Phase 2 · completed
- NCT04362189 — Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04798066 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hope Biosciences Research Foundation
- Last refreshed: 29 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04798066.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing